Electromed, Inc. reported a significant increase in financial performance for the three months ended September 30, 2025, with net revenues reaching $16.9 million, a 15.1% increase from $14.7 million in the same period last year. The company's gross profit also rose to $13.2 million, representing 78.1% of net revenues, compared to $11.5 million or 78.3% of net revenues in the prior year. Net income for the quarter was $2.1 million, a 44.9% increase from $1.5 million in the previous year, resulting in earnings per share of $0.26, up from $0.17.
The increase in revenue was driven primarily by growth in the homecare segment, which saw a 12.7% rise to $14.9 million, attributed to a higher number of direct sales representatives and increased revenue per representative. Hospital sales surged by 51.7% to $1.0 million, reflecting a growing demand for capital and disposable products, while homecare distributor revenue increased by 41.2% to $829,000 due to a larger distribution network. However, other revenue declined by 32.2% to $122,000, mainly due to reduced purchases from international distributors.
Electromed's operational metrics indicate a strategic focus on expanding its sales force and enhancing product offerings. The company averaged 57 homecare field sales representatives during the quarter, contributing to the revenue growth. Additionally, the SmartVest Clearway® Airway Clearance System, which received FDA clearance in November 2022, continues to be a key product in their portfolio, targeting patients with chronic pulmonary conditions. The company has also initiated a stock repurchase program, authorizing up to $10 million for share buybacks, with $1.0 million spent on repurchasing shares in the current quarter.
On the balance sheet, total assets decreased slightly to $53.6 million from $53.8 million at the end of June 2025. Current liabilities also fell to $8.8 million from $10.5 million, while shareholders' equity increased to $44.7 million, up from $43.2 million. The company reported cash and cash equivalents of $14.1 million, down from $15.3 million, reflecting cash used in financing activities, including share repurchases.
Looking ahead, Electromed anticipates continued growth driven by its expanding sales force and product innovations. The company believes its current working capital and available credit will support its operational needs for the next twelve months. However, it acknowledges potential risks, including changes in reimbursement policies and market competition, which could impact future performance. The company remains committed to evaluating its financial strategies to ensure adequate liquidity and operational stability.
About Electromed, Inc.
Electromed, Inc. develops, manufactures, and markets the SmartVest airway clearance system, primarily serving patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions. Its products use high-frequency chest wall oscillation (HFCWO) to improve respiratory function, reduce infections, and lower healthcare costs. The company employs a direct-to-patient and provider sales model, focusing on clinical evidence, reimbursement support, and product innovation in the U.S. and select international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.